3 Exhaust Systems Maker, Diagnostics Chain and Food and Pharma Ingredients Maker Stocks With a Strong Future Roadmap: Sharda Motor Industries, Vijaya Diagnostic Centre and Sudeep Pharma

Exhaust, diagnostics and ingredient stocks bring together companies with a visible plan for the years ahead. Sharda Motor Industries, Vijaya Diagnostic Centre and Sudeep Pharma cover an exhaust systems maker, a diagnostics chain and a food and pharma ingredients maker.

This list covers three exhaust, diagnostics and ingredient stocks with complete current figures: Sharda Motor Industries, Vijaya Diagnostic Centre and Sudeep Pharma. Every figure comes from the latest reported financials and the 11 November 2026 market close. Companies without complete current figures were left out.

Click Here – Get Free Investment Predictions

What Are Exhaust, Diagnostics and Ingredient Stocks?

Exhaust, diagnostics and ingredient stocks are listed companies that make exhaust and emission systems for vehicles, run diagnostic centres across many cities, and make dairy, food and pharma ingredients. Their earnings depend on vehicle output, test volumes and ingredient demand.

Exhaust, Diagnostics and Ingredient Stocks at a Glance

On valuation, Sharda Motor Industries trades at a P/E below the industry P/E, while Vijaya Diagnostic Centre and Sudeep Pharma trade above it, which reflects the growth the market already expects. Readers comparing exhaust, diagnostics and ingredient stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain. With the Q2 FY27 results season close, investors in exhaust, diagnostics and ingredient stocks can use the coming numbers to test whether growth is holding.

Why Do Exhaust, Diagnostics and Ingredient Stocks Have a Strong Roadmap in India?

Exhaust, diagnostics and ingredient stocks have a strong roadmap in India because tighter emission norms, rising use of preventive tests and growing demand for processed food keep widening the market for these companies.

• Exhaust systems. Emission rules need advanced systems.
• Diagnostics. Doctors order more tests for early care.
• Ingredients. Food and drug makers need quality inputs.

Why Sharda Motor Industries Features Among These Exhaust, Diagnostics and Ingredient Stocks

Among the exhaust, diagnostics and ingredient stocks on this list, Sharda Motor Industries makes exhaust systems and catalytic converters, with large passenger vehicle makers among its main customers.

The company has a return on equity of 26.3%, a debt to equity ratio of 0.04 and a market capitalisation of Rs 4,995 crore. The stock trades at a P/E of 15.0, below the industry P/E of 36.9.

Revenue rose from Rs 2,285 crore in FY22 to Rs 3,483 crore in FY26, a compound annual growth rate of 11.1%. Net profit grew from Rs 149 crore in FY22 to Rs 345 crore in FY26, which works out to a compound annual growth rate of 23.3%. In the June 2026 quarter, revenue grew 33.2% year on year to Rs 1,038 crore.

Roadmap: Tighter emission norms increase the content per vehicle for exhaust systems and catalysts. The company is adding capacity in line with its customers' production plans and expanding into new product lines, which broadens its revenue base.

What to watch: Follow volume trends at its key customers and precious metal price movements.

Why Vijaya Diagnostic Centre Features Among These Exhaust, Diagnostics and Ingredient Stocks

Among the silencer, test lab and flavour shares on this list, Vijaya Diagnostic Centre is a Hyderabad-headquartered diagnostics chain that offers pathology and radiology services through a network of centres, with Hyderabad and Telangana as its home base.

Revenue rose from Rs 475 crore in FY22 to Rs 835 crore in FY26, a compound annual growth rate of 15.1%. Net profit grew from Rs 111 crore in FY22 to Rs 173 crore in FY26, which works out to a compound annual growth rate of 11.8%.

In the June 2026 quarter, revenue grew 22.8% year on year to Rs 240 crore, while net profit rose 37.6% to Rs 53.1 crore. The company has a return on equity of 18.1%, a debt to equity ratio of 0.44 and a market capitalisation of Rs 14,066 crore. The stock trades at a P/E of 75.0, above the industry P/E of 59.6.

Roadmap: The plan is to deepen its network in existing clusters and extend the Vijaya brand into new regions, adding imaging modalities and wellness packages that raise revenue per patient. Diagnostics is a fragmented business, so organised chains with strong brands keep gaining share.

What to watch: Check the revenue contribution from newer regions and the pace at which new centres turn profitable.

Why Sudeep Pharma Features Among These Exhaust, Diagnostics and Ingredient Stocks

Among the three companies on this list, Sudeep Pharma makes pharmaceutical excipients, food ingredients and nutritional additives such as minerals and fortification products for domestic and global customers.

In the June 2026 quarter, revenue grew 25.9% year on year to Rs 164 crore, while net profit rose 29.8% to Rs 40.6 crore. Revenue rose from Rs 350 crore in FY22 to Rs 671 crore in FY26, a compound annual growth rate of 17.6%.

Net profit grew from Rs 50.2 crore in FY22 to Rs 174 crore in FY26, which works out to a compound annual growth rate of 36.5%. The company has a return on equity of 19.6%, a debt to equity ratio of 0.17 and a market capitalisation of Rs 11,352 crore. The stock trades at a P/E of 61.8, above the industry P/E of 35.1.

Roadmap: Excipients and nutritional ingredients are in steady demand from pharma and food customers, and the company is a leading supplier in its niche. Capacity additions and regulatory approvals open up new export markets.

What to watch: Check capacity expansion progress and export revenue growth.

Sharda Motor Industries vs Vijaya Diagnostic Centre vs Sudeep Pharma on Key Financials

The table below sets the three exhaust, diagnostics and ingredient stocks side by side on revenue, profit and margin, using reported figures.

Sharda Motor Industries posts the highest return on equity in this group at 26.3%. Sharda Motor Industries has the largest FY26 revenue at Rs 3,483 crore, and Sudeep Pharma shows the fastest revenue growth with a 17.6% compound annual rate. A useful habit with exhaust, diagnostics and ingredient stocks is to check each new quarterly result against the capacity plans the company described earlier.

The June 2026 quarter, the latest reported, gives a fresh read on momentum:

Key Risks to Check Before Investing in Exhaust, Diagnostics and Ingredient Stocks

Every theme carries risks that deserve a check before any decision. For these exhaust, diagnostics and ingredient stocks, the main points are: Long-term silencer, test lab and flavour shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.

• Production cycles. Vehicle output can vary with demand.
• Test volumes. Footfall and test mix can vary with seasons.
• Raw material costs. Ingredient and packaging prices can move margins.

Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.

Use the Univest Stock Screener to filter exhaust, diagnostics and ingredient stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.

Final Thoughts on Exhaust, Diagnostics and Ingredient Stocks

Exhaust, diagnostics and ingredient stocks suit investors who prefer to study business strength before price moves. Sharda Motor Industries, Vijaya Diagnostic Centre and Sudeep Pharma each have a clear plan to grow. Based on the 11 November 2026 close, Sharda Motor Industries trades at Rs 903.85, Vijaya Diagnostic Centre at Rs 1,423.8 and Sudeep Pharma at Rs 1,207.7. Valuation matters as much as growth, so compare each company's P/E with its industry P/E before adding any of these exhaust, diagnostics and ingredient stocks to a watchlist.

Download the Univest iOS App or Univest Android App to track exhaust, diagnostics and ingredient stocks, set price alerts and get research-backed stock ideas.

What are exhaust, diagnostics and ingredient stocks?

Ans. Exhaust, diagnostics and ingredient stocks are listed companies that make exhaust and emission systems for vehicles, run diagnostic centres across many cities, and make dairy, food and pharma ingredients. Their earnings depend on vehicle output, test volumes and ingredient demand. This list looks at three of them, Sharda Motor Industries, Vijaya Diagnostic Centre and Sudeep Pharma, using reported FY22 to FY26 financials and the 11 November 2026 closing prices.

Which exhaust, diagnostics and ingredient stocks are covered in this list?

Ans. This list covers Sharda Motor Industries, Vijaya Diagnostic Centre and Sudeep Pharma. Based on the 11 November 2026 close, Sharda Motor Industries traded at Rs 903.85, Vijaya Diagnostic Centre at Rs 1,423.8 and Sudeep Pharma at Rs 1,207.7. Their return on equity ranges from 18.1% to 26.3%, and their revenue compound annual growth from FY22 to FY26 ranges from 11.1% to 17.6%.

Why do exhaust, diagnostics and ingredient stocks have a strong future roadmap in India?

Ans. Exhaust, diagnostics and ingredient stocks have a strong roadmap in India because tighter emission norms, rising use of preventive tests and growing demand for processed food keep widening the market for these companies. The main drivers are as follows. Exhaust systems. Emission rules need advanced systems. Diagnostics. Doctors order more tests for early care. Ingredients. Food and drug makers need quality inputs. Together these factors give the companies on this list a visible path for growth over the coming years.

How has Sharda Motor Industries performed financially?

Ans. Revenue rose from Rs 2,285 crore in FY22 to Rs 3,483 crore in FY26, a compound annual growth rate of 11.1%. Net profit grew from Rs 149 crore in FY22 to Rs 345 crore in FY26, which works out to a compound annual growth rate of 23.3%. In the June 2026 quarter, revenue grew 33.2% year on year to Rs 1,038 crore. The company has a return on equity of 26.3%, a debt to equity ratio of 0.04 and a market capitalisation of Rs 4,995 crore. The stock trades at a P/E of 15.0, below the industry P/E of 36.9. Looking ahead, tighter emission norms increase the content per vehicle for exhaust systems and catalysts. The company is adding capacity in line with its customers' production plans and expanding into new product lines, which broadens its revenue base.

How has Vijaya Diagnostic Centre performed financially?

Ans. Revenue rose from Rs 475 crore in FY22 to Rs 835 crore in FY26, a compound annual growth rate of 15.1%. Net profit grew from Rs 111 crore in FY22 to Rs 173 crore in FY26, which works out to a compound annual growth rate of 11.8%. In the June 2026 quarter, revenue grew 22.8% year on year to Rs 240 crore, while net profit rose 37.6% to Rs 53.1 crore. The company has a return on equity of 18.1%, a debt to equity ratio of 0.44 and a market capitalisation of Rs 14,066 crore. The stock trades at a P/E of 75.0, above the industry P/E of 59.6. Looking ahead, the plan is to deepen its network in existing clusters and extend the Vijaya brand into new regions, adding imaging modalities and wellness packages that raise revenue per patient. Diagnostics is a fragmented business, so organised chains with strong brands keep gaining share.

How has Sudeep Pharma performed financially?

Ans. Revenue rose from Rs 350 crore in FY22 to Rs 671 crore in FY26, a compound annual growth rate of 17.6%. Net profit grew from Rs 50.2 crore in FY22 to Rs 174 crore in FY26, which works out to a compound annual growth rate of 36.5%. In the June 2026 quarter, revenue grew 25.9% year on year to Rs 164 crore, while net profit rose 29.8% to Rs 40.6 crore. The company has a return on equity of 19.6%, a debt to equity ratio of 0.17 and a market capitalisation of Rs 11,352 crore. The stock trades at a P/E of 61.8, above the industry P/E of 35.1. Looking ahead, excipients and nutritional ingredients are in steady demand from pharma and food customers, and the company is a leading supplier in its niche. Capacity additions and regulatory approvals open up new export markets.

What risks should investors check before buying exhaust, diagnostics and ingredient stocks?

Ans. Investors should check a few risks before buying exhaust, diagnostics and ingredient stocks. Production cycles. Vehicle output can vary with demand. Test volumes. Footfall and test mix can vary with seasons. Raw material costs. Ingredient and packaging prices can move margins. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.

Is this list of exhaust, diagnostics and ingredient stocks investment advice?

Ans. No. This article is educational and uses publicly available data as of the 11 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.